INAB on Nasdaq

IN8BIO, INC.

We are a leading clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of gamma-delta T cellular therapy product candidates and gamma-delta T cell.5 From its latest annual report

Price unavailable

Last updated Oct 19, 2026.

Overview

-$19.4MNet income, fiscal 20253

Compare with another stock.

  • TickerINAB on Nasdaq2
  • IndustryBiological Products, (No Diagnostic Substances)2
  • HeadquartersNew York, United States2
  • Incorporated inDE4
  • Business addressEmpire State Building, 350 5Th Avenue, Suite 5330, New York, Ny 101184
  • Filer categoryNon-accelerated filer, Smaller reporting company, Emerging growth company4
  • Legal formCorporation2
  • LEI549300H68IVCRKSGSL942
  • StatusActive2
  • LEI statusLapsed (not renewed)2
  • Registered addressC/O THE CORPORATION TRUST COMPANY, 19801 Wilmington, United States2
  • Registered withDivision of Corporations, Department of State, 68743422

See how the biggest companies compare on our leaderboards

We are a leading clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of gamma-delta T cellular therapy product candidates and gamma-delta T cell engagers ("TCEs") for cancer and autoimmune diseases. Gamma-delta T cells are a specialized population of T cells that possess unique properties. They are naturally occurring immune cells that can intrinsically regulate immune responses and have the ability to differentiate between healthy and diseased tissue. These cells serve as a functional bridge between innate and adaptive immunity, contributing to direct tumor-killing as well as immune cell recruitment and activation to drive deeper, more comprehensive immune responses. Multiple studies have demonstrated the robust tumor-killing ability of gamma-delta T cells and superior outcomes in cancer patients with elevated levels of gamma-delta T cell…5 From its latest annual report

Financials

From the company’s reports to the SEC. Every number links to the filing it came from.

Key numbers, fiscal 2025

-70.5%Return on equity3

Financial statements

Operating income67893-$19.4M in 2025+127% since 2020
-$40.0M-$30.0M-$20.0M-$10.0M02020: -$8.6M-$8.6M20202021: -$14.7M-$14.7M2021+71%2022: -$28.5M-$28.5M2022+95%2023: -$30.0M-$30.0M2023+5%2024: -$30.4M-$30.4M2024+1%2025: -$19.4M-$19.4M2025−36%
Net income67893-$19.4M in 2025+127% since 2020
-$40.0M-$30.0M-$20.0M-$10.0M02020: -$8.6M-$8.6M20202021: -$14.7M-$14.7M2021+71%2022: -$28.5M-$28.5M2022+95%2023: -$30.0M-$30.0M2023+5%2024: -$30.4M-$30.4M2024+1%2025: -$19.4M-$19.4M2025−36%

Every line of the income statement as filed: the last 2 fiscal years, latest first.3

Period ending2025-12-312024-12-31
Research and development$10.2M$17.0M
General and administrative$9.7M$12.6M
Severance and related charges$0$1.1M
Total operating expenses$19.9M$30.7M
Interest income$421.0K$230.0K
Loss from operations-$19.4M-$30.4M
Net loss-$19.4M-$30.4M
Net loss per share - basic-$4.44-$17.05
Net loss per share - diluted-$4.44-$17.05
Weighted-average number of shares used in computing net loss per common share - basic4.4M shares1.8M shares
Weighted average number of shares used in computing net loss per share - diluted4.4M shares1.8M shares

Compare IN8BIO, INC. with another company

Leadership

Who has led IN8BIO, INC., and when. Pick a name to see everywhere that person has worked.

President

  1. Kate Rochlin2026–now

Chief operating officer

  1. Kate Rochlin2021–now
2025
Board members and other officers (12)

Named in SEC Form D filings

People the company listed in its private-offering notices.

  • Executive OfficerPatrick McCall named Dec 28, 2023 to Dec 30, 202526
  • Executive Officer, DirectorWilliam Ho named Dec 28, 2023 to Dec 30, 202526

Former names

  • Incysus Therapeutics, Inc.May 22, 2018 to Sep 20, 20184

Timeline

  1. May 7, 2018Founded IN8BIO, INC. is founded2

Filings

350 filings to the SEC since October 2021: 6 annual reports, 15 quarterly reports, 74 major events, 158 insider forms, 26 large holders, 3 private raises, 68 other. The latest 20:

  1. Aug 13, 2026SCHEDULE 13G/A EDGAR
  2. Aug 7, 2026S-8 EDGAR
  3. Aug 6, 202610-Q EDGAR
  4. Aug 6, 20268-K EDGAR
  5. Jun 1, 20268-K EDGAR
  6. Jun 1, 2026424B5 EDGAR
  7. May 29, 2026SCHEDULE 13D/A EDGAR
  8. May 29, 20264 EDGAR
  9. May 19, 2026EFFECT EDGAR
  10. May 18, 2026S-3/A EDGAR
  11. May 15, 2026CORRESP EDGAR
  12. May 12, 20264 EDGAR
  13. May 12, 20264 EDGAR
  14. May 12, 20264 EDGAR
  15. May 12, 20264 EDGAR
  16. May 12, 20264 EDGAR
  17. May 12, 20264 EDGAR
  18. May 12, 20264 EDGAR
  19. May 12, 20264 EDGAR
  20. May 12, 20264 EDGAR

The 350 filings since October 2021 can be filtered by form type and year here when JavaScript is on.

Every filing from the last five years, summarized. The full record is on SEC EDGAR.

Insider trades

24 open-market trades by officers, directors and large owners since October 2021: 24 buys and 0 sales. Grants, option exercises and gifts are left out.

DateWhoTradeSharesPriceValueFiling
Sep 13, 2023Graff Jeremy R.DirectorBuy2,500$0.95$2.4KForm 4
Aug 25, 2023McCall PatrickCHIEF FINANCIAL OFFICERBuy1,000$1.03$1.0KForm 4
Aug 24, 2023Ho William Tai-WeiCEOBuy23,800$1.05$25.0KForm 4
Dec 12, 2022Kreis Leslie W.10% ownerBuy75,001$2.48$186.0KForm 4
Dec 12, 2022BIOS Fund III QP, LP10% ownerBuy75,001$2.48$186.0KForm 4
Sep 28, 2022BIOS Fund II NT, LP10% ownerBuy25,000$2.02$50.5KForm 4
Sep 28, 2022Bios Equity Partners II, LP10% ownerBuy25,000$2.02$50.5KForm 4
Aug 29, 2022BIOS Fund II QP, LP10% ownerBuy40,000$2.02$80.8KForm 4
Aug 29, 2022Cavu Advisors, LLC10% ownerBuy40,000$2.02$80.8KForm 4
Aug 26, 2022BIOS Fund II QP, LP10% ownerBuy11,214$2.01$22.5KForm 4
Aug 26, 2022Cavu Advisors, LLC10% ownerBuy11,214$2.01$22.5KForm 4
Aug 17, 2022BIOS Fund II NT, LP10% ownerBuy50,000$1.93$96.5KForm 4
Aug 17, 2022Cavu Management, LP10% ownerBuy50,000$1.93$96.5KForm 4
Aug 16, 2022Transcend Partners Opportunity Fund LLC10% ownerBuy789,473$1.90$1.5MForm 4
Aug 16, 2022Ho William Tai-WeiCEOBuy26,315$1.90$50.0KForm 4
Aug 16, 2022Rochlin KatePresident and COOBuy5,263$1.90$10.0KForm 4
Aug 16, 2022McCall PatrickCHIEF FINANCIAL OFFICERBuy5,263$1.90$10.0KForm 4
Aug 16, 2022Goswami TrishnaChief Medical OfficerBuy2,631$1.90$5.0KForm 4
Aug 16, 2022Lamb LawrenceEVP and CSOBuy526$1.90$999Form 4
Aug 16, 2022Greenwood LubaDirectorBuy526$1.90$999Form 4

All 24 trades can be filtered by person here when JavaScript is on.

From Forms 4 filed with the SEC.

Major holders

Investors who own more than 5% of the shares must tell the SEC: a 13D if they may seek to influence the company, a 13G if they hold passively.

Money raised

Private offerings the company reported to the SEC on Form D.

  1. Dec 22, 2025Raised $20.1 million in a private offering of equity Form D: $40.2 million offered in all Form D
  2. Oct 4, 2024Raised $12.4 million in a private offering of equity Form D: 73 investors so far Form D
  3. Dec 13, 2023Raised $14.4 million in a private offering of equity Form D: 20 investors so far Form D

Held by these funds

The largest holders among investment managers' 13F reports for the quarter ending Jun 30, 2026. Change is in shares since the quarter before.

FundSharesValueShare of the fundChange
Alyeska Investment Group, L.P.944,319$1.3M0.0%No change
Franklin Resources Inc914,531$1.3M0.0%No change
683 Capital Management, LLC724,637$1.0M0.1%No change
Stonepine Capital Management, LLC695,287$980.4K0.7%+31,875
Vanguard Capital Management LLC88,865$126.5K0.0%No change
BIOS Capital Management, LP80,957$114.1K0.3%−86,848
Geode Capital Management, LLC72,550$102.3K0.0%−13,689
Citadel Advisors LLC63,055$88.9K0.0%New
Oppenheimer & Co Inc63,042$88.9K0.0%+39,009
Vanguard Fiduciary Trust Co43,570$62.0K0.0%No change
Captrust Financial Advisors33,295$46.9K0.0%No change
Texas Capital Bank Wealth Management Services Inc24,406$34.4K0.0%+656
Northern Trust Corp21,734$30.6K0.0%+1,294
Renaissance Technologies LLC12,100$17.1K0.0%New
Tower Research Capital LLC (TRC)3,738$5.3K0.0%+2,473
Northwestern Mutual Wealth Management Co2,785$3.9K0.0%No change
Jones Financial Companies Lllp768$1.0K0.0%No change
BlackRock, Inc.84$1180.0%No change
Rockefeller Capital Management L.P.83$1170.0%No change
Barclays PLC28$390.0%New
UBS Group AG1$10.0%−479

13F reports cover disclosed long positions in U.S. stocks only.

Sources

The numbers on this page point here. Each one links to the record it came from.

  1. 1
  2. 2
  3. 3
  4. 4
  5. 5
  6. 6
  7. 7
  8. 8
  9. 9
  10. 10
  11. 11
  12. 12
  13. 13
  14. 14
  15. 15
  16. 16
  17. 17
  18. 18
  19. 19
  20. 20
  21. 21
  22. 22
  23. 23
  24. 24
  25. 25
  26. 26
  27. 27
  28. 28
  29. 29
  30. 30
  31. 31
  32. 32
  33. 33
  34. 34
  35. 35
  36. 36